Alpha-Blockers Impact Stent-Related Symptoms: A Randomized, Double-Blind, Placebo-Controlled Trial

Nazim, Mohammad; Ather, M Hammad

doi:10.1089/end.2012.0036

Cited by 24 publications

(38 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of the results of statistical analysis, significant differences in IPSS voiding symptom sub-scores (MD, -2.66; 95% CI, -4.36 to -0.96) were detected; however, no significant differences in IPSS storage symptom sub-scores (MD, -0.93; 95% CI, -2.28 to 0.43) were detected (Table IV). The pooled USSQ urinary symptoms score data (MD, -5.84; 95% CI, -9.35 to-2.33) for seven studies (13,16,(22)(23)(24)(25)30) demonstrated that α 1 -blockers administration significantly reduced USS.…”

Section: Resultsmentioning

confidence: 99%

“…A Russian article published in Urologiia met the inclusion criteria according to the English abstract in PubMed; however it was subsequently excluded, since the full text could not be located (21). A total of 14 RCTs including 1,075 patients were included in the present meta-analysis (13,15,16,(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32).…”

Section: Resultsmentioning

confidence: 99%

“…sub-scores, five trials (15,26,27,29,32) employed voiding symptoms sub-scores, and seven trials (13,16,(22)(23)(24)(25)30) evaluated USSQ urinary symptoms scores in order to evaluate the effectiveness of α 1 -adrenoceptor antagonists as therapeutic agents for patients with USS. VAPS was adopted in nine studies (13,15,16,23,25,26,28,30,32) and USSQ pain score was applied in six trials (13,16,(22)(23)(24)(25) In eight studies, analgesics and/or antibiotics were used in all patients as a general therapy.…”

Section: Resultsmentioning

confidence: 99%

“…VAPS was adopted in nine studies (13,15,16,23,25,26,28,30,32) and USSQ pain score was applied in six trials (13,16,(22)(23)(24)(25) In eight studies, analgesics and/or antibiotics were used in all patients as a general therapy. No significant differences in the rates of employment and sexual activity were demonstrated between the treatment groups.…”

Section: Resultsmentioning

confidence: 99%

“…In order to evaluate the intensity of pain experienced by patients with an indwelling ureteral stent in the included studies, three approaches, the USSQ, VAPS and SF-36 pain scores, were used. VAPS data from nine studies (13,15,16,23,25,26,28,30,32) were pooled and a random effects model demonstrated a significant difference between the α 1 -blocker and control groups (MD, -1.53; 95% CI, -2.25 to -0.80) (Table IV); however, no significant differences were detected following sensitivity analysis. Similarly, USSQ pain scores (MD, -3.97; 95% CI, -5.52 to -2.42) (Table IV) were significantly decreased in patients treated with α 1 -blockers.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

α1-blockers for the reduction of ureteric stent-related symptoms: A systematic review and meta-analysis

Zhang

Cheng

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The present meta-analysis aimed to evaluate the current evidence for the use of α 1 -blockers in relieving ureteric stent-related symptoms (USS). Electronic databases, including PubMed, Embase and Cochrane Library, were searched and two independent reviewers identified relevant parallel randomized controlled trials (RCTs), assessed trial quality and extracted data. Review Manager (version 5.2) was used to conduct a meta-analysis of the data. Significant advantages were demonstrated in the treatment group based on International Prostate Symptom Score (IPSS), voiding symptom sub-scores [mean difference (MD), -2.66; 95% confidence interval (CI), (-4.36, -0.96)], Ureteral Stent Symptom Questionnaire (USSQ) urinary symptoms score (MD, -5.84; 95%CI, -9.35 to -2.33), IPSS quality of life score (MD, -1.46; 95%CI, -2.64 to -0.28) USSQ quality of life score (MD, -0.69; 95%CI, -1.10 to -0.28), USSQ pain score (MD, -3.97; 95%CI, -5.52 to -2.42), Visual Analog Pain Scale (MD, -1.53; 95%CI, -2.25 to -0.80) and USSQ general health score (MD, -1.82; 95%CI, -2.47 to -1.18). No significant differences were detected from the following results: IPSS storage symptom sub-score (MD, -0.93; 95%CI, -2.28 to 0.43), USSQ sexual matters score (MD, -0.10; 95%CI, -0.79 to 0.59), USSQ work performance score (MD, 1.64; 95%CI, and USSQ additional problems score (MD, -2.02; 95%CI, -4.55 to 0.52). However, significant between-trial heterogeneity was detected following statistical analysis and there were insufficient data to trace its source. The existing RCT data supported the hypothesis that α 1 -blockers beneficially influence pain, urinary symptoms and the quality of life of patients with an indwelling ureteral stent.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

α1-blockers for the reduction of ureteric stent-related symptoms: A systematic review and meta-analysis

Zhang

Cheng

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

Ureteral Stent‐Related Symptoms and Pharmacotherapy: A Brief Narrative Review

Bellos,

Katsimperis,

Kapsalos‐Dedes

et al. 2023

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The purpose of this article is to review the effects of different types of pharmacotherapy on symptoms that affect the quality of a patient's life after stent insertion. A thorough Medline/PubMed nonsystematic review was conducted from 1987 to January 2023, using the terms: “pigtail” OR “ureteral stents” AND “lower urinary tracts symptoms” OR “LUTS” AND “pharmacotherapy” OR “drugs”. Relevant studies conducted in humans and reported in English language were included. The available reviews and articles associating the use of drugs with stent‐related symptoms (SRS) provide conflicting results. Most of them show a clear benefit of alpha blockers, particularly alfuzosin, on treating urinary SRS, and hence there is a strong recommendation for the use of alpha blockers for the treatment of SRS in the guidelines of the European Association of Urology. Anticholinergics and mirabegron have shown a significant benefit in dealing with irritative bladder symptoms. In contrast, the findings for combination therapies are contradictory, with some studies showing that combination therapy is no superior to monotherapy with regards to most of the subsets of the Ureteral Stent Symptom Questionnaire (USSQ), whereas others present a clear benefit of combination therapies, specifically silodosin and solifenacin, in treating stent‐associated lower urinary tract symptoms (LUTS), in comparison with any other type of monotherapy or combination therapy. Many studies suggest that some categories of pharmacotherapy, such as alpha blockers, can alleviate SRS. However, there is conflicting evidence concerning most other types of medical treatment. Randomized trials with the largest number of patients are needed to investigate the effectiveness of novel approaches on SRS.

show abstract

Ureteral Stents

Chew¹,

Paterson²,

Lange³

2014

Ureteral Stone Management

View full text Add to dashboard Cite

Alpha-Blockers Impact Stent-Related Symptoms: A Randomized, Double-Blind, Placebo-Controlled Trial

Abstract: Alfuzosin 10 mg once daily in patients with a Double-J stent significantly decreases the bothersome urinary symptoms, besides decreasing significantly the pain associated with the stent.

Cited by 24 publications

References 18 publications

α1-blockers for the reduction of ureteric stent-related symptoms: A systematic review and meta-analysis

α1-blockers for the reduction of ureteric stent-related symptoms: A systematic review and meta-analysis

Ureteral Stent‐Related Symptoms and Pharmacotherapy: A Brief Narrative Review

Ureteral Stents

Contact Info

Product

Resources

About